Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
Lucid Diligence Brief: Hologic acquisition by Blackstone and TPG
Lucid Diligence Brief: Hologic acquisition by Blackstone and TPG Professional…
Lucid Diligence Brief: HealthVerity and Claritas Rx partnership
Lucid Diligence Brief: HealthVerity and Claritas Rx partnership Professional…
Lucid Diligence Brief: Kardigan $254m Series B
Lucid Diligence Brief: Kardigan $254m Series B Professional audiences only. Not…
Lucid Diligence Brief: Samsung and GRAIL LOI, Galleri MCED rollout in Asia
Lucid Diligence Brief: Samsung and GRAIL LOI, Galleri MCED rollout in Asia…
Lucid Diligence Brief: EVOQ x Sanofi collaboration
Lucid Diligence Brief: EVOQ x Sanofi collaboration Professional audiences only.…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Lucid Diligence Brief: Kailera Therapeutics $600m Series B
Lucid Diligence Brief: Kailera Therapeutics $600m Series B Professional…
Lucid Diligence Brief: Excellergy ECRIs, $70M investment
Lucid Diligence Brief: Excellergy ECRIs, $70M investment Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital Therapeutics
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital…
How we worked with a multinational Pharma company toward successful market entry in select EU and Latin America countries.
The challenge: Entering a new market. The fine line between "go" and "no-go". A…
